Associated Papers
Analytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients.
Fan F et al.
Cancer Medicine, 2024
A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants.
Aboulkassim T et al.
Cell Reports, 2023
KEAP1 Cancer Mutants: A Large-Scale Molecular Dynamics Study of Protein Stability.
Wilson CJ et al.
International Journal of Molecular Sciences, 2021
SinoDuplex: An Improved Duplex Sequencing Approach to Detect Low-frequency Variants in Plasma cfDNA Samples.
Ren Y et al.
Genomics, Proteomics & Bioinformatics, 2020
32428603 (PubMed )
Supplement: mmc6.xlsx › HD701
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R et al.
Plos One, 2020
32976510 (PubMed )
Supplement: pone.0237802.s009.zip › Table_9_Accuracy_Short_Variant_Line_Data.xlsx › sheet_1
Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1.
Khan H et al.
The Biochemical Journal, 2015
Somatic mutations of the KEAP1 gene in common solid cancers.
Yoo NJ et al.
Histopathology, 2012
Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.
Taguchi K et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms, 2011
Select a paper to view details